US LNG exports surge but will buyers in China turn up?
Investing.com -- SCHOTT Pharma on Tuesday preannounced its third-quarter results ahead of the full release on August 12, showing strong margin performance despite modest revenue growth.
The company reported sales of €256 million in Q3, representing a 1% year-over-year increase on a reported basis and 3% growth at constant exchange rates.
EBITDA rose 11% to €83 million, with the EBITDA margin expanding to 32.4% from 29.4% in the same period last year.
The strong margin performance was driven by a favorable product mix, with High Value Solutions (HVS) now accounting for 60% of total sales, up 5 percentage points from the previous year.
HVS includes sterile cartridges and specialty vials, which carry higher margins than standard products.
For the full fiscal year 2025, SCHOTT Pharma has narrowed its revenue growth guidance to approximately 6% organic growth at constant exchange rates, down from its previous "high-single-digit" forecast.
This adjustment reflects increased macroeconomic uncertainty and cautious industry sentiment amid global policy discussions.
Despite the more conservative revenue outlook, the company raised its EBITDA margin guidance to approximately 28%, up from its previous expectation of maintaining the prior year’s level of about 26.9%.
This increase suggests confidence in the company’s ability to continue improving its product mix and control costs effectively.
The company will release its complete third-quarter results on August 12.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.